OBJECTIVE To explore the potential mechanism of Cigu Xiaozhi Prescription(CGXP)in the treatment of non-alco-holic steatohepatitis(NASH)liver fibrosis.METHODS A NASH mouse model was established.The degree of liver enlargement was evaluated by calculating the liver index.Hematoxylin-eosin(HE)and Masson staining were used to observe the degree of liver fibro-sis.In addition,immunohistochemistry was employed to detect the expression of liver fibrosis-related proteins,including α-SMA,Collagen 1,MMP2,and MMP9.Western blot and qPCR techniques were used to detect the expression levels of HIF-1α,E-cadher-in,N-cadherin,Shh,Smo,Gli1,and Gli2 in the mouse liver.The alkaline hydrolysis method was used to measure the content of liv-er hydroxyproline.RESULTS CGXP could effectively reduce the liver index(P<0.001),alleviate liver enlargement and inflamma-tion,and significantly improve the pathological damage of liver tissue in mice with liver fibrosis.CGXP significantly decreased the ex-pression levels of liver fibrosis-related proteins α-SMA,Collagen 1,MMP2 and MMP9(P<0.01,P<0.000 1);reduced the levels of HIF-1α,E-cadherin,N-cadherin,Shh,Smo,Gli1,and Gli2,and the therapeutic effect of high-dose CGXP was particularly significant(P<0.05,P<0.01,P<0.001,P<0.000 1).CONCLUSION CGXP can relieve NASH liver fibrosis in mice by reducing the liver index,alleviating inflammation,and improving tissue pathological damage.The mechanism may be related to the inhibition of the Hedgehog signaling pathway,which alters the activation and proliferation of hepatic stellate cells and reduces the synthesis and dep-osition of extracellular matrix.

OBJECTIVE To explore the potential mechanism of Cigu Xiaozhi Prescription(CGXP)in the treatment of non-alco-holic steatohepatitis(NASH)liver fibrosis.METHODS A NASH mouse model was established.The degree of liver enlargement was evaluated by calculating the liver index.Hematoxylin-eosin(HE)and Masson staining were used to observe the degree of liver fibro-sis.In addition,immunohistochemistry was employed to detect the expression of liver fibrosis-related proteins,including α-SMA,Collagen 1,MMP2,and MMP9.Western blot and qPCR techniques were used to detect the expression levels of HIF-1α,E-cadher-in,N-cadherin,Shh,Smo,Gli1,and Gli2 in the mouse liver.The alkaline hydrolysis method was used to measure the content of liv-er hydroxyproline.RESULTS CGXP could effectively reduce the liver index(P<0.001),alleviate liver enlargement and inflamma-tion,and significantly improve the pathological damage of liver tissue in mice with liver fibrosis.CGXP significantly decreased the ex-pression levels of liver fibrosis-related proteins α-SMA,Collagen 1,MMP2 and MMP9(P<0.01,P<0.000 1);reduced the levels of HIF-1α,E-cadherin,N-cadherin,Shh,Smo,Gli1,and Gli2,and the therapeutic effect of high-dose CGXP was particularly significant(P<0.05,P<0.01,P<0.001,P<0.000 1).CONCLUSION CGXP can relieve NASH liver fibrosis in mice by reducing the liver index,alleviating inflammation,and improving tissue pathological damage.The mechanism may be related to the inhibition of the Hedgehog signaling pathway,which alters the activation and proliferation of hepatic stellate cells and reduces the synthesis and dep-osition of extracellular matrix.

Objective:To summarize the clinical manifestations and diagnosis, treatment experience of vertically transmitted eschar-free scrub typhus in newborns.Methods:A case summary was made.The clinical data of 3 newborns clinically diagnosed as vertically transmitted eschar-free scrub typhus and treated at the Department of Neonatology, the Sixth Affiliated Hospital, Sun Yat-sen University Yuexi Hospital/Xinyi People′s Hospital from August 2022 to July 2024 were retrospectively analyzed.Results:The age of onset of scrub typhus in the 3 newborns was within 24 h after birth.The children presented a fever, the clinical manifestations of early onset sepsis, and also multiple organ damage.Laboratory examination showed that all the 3 children have an abnormal elevation in C-reactive protein, a decrease of blood platelet (PLT) and an increase in D-dimer within 24 h after birth.The diagnosis was confirmed in all the patients via the metagenomic sequencing technology of pathogenic microorganism of blood samples.Two of the 3 children presented hepatomegaly and were treated with Azithromycin.All the children were clinically cured finally.Conclusions:The early clinical manifestation of vertically transmitted eschar-free scrub typhus in newborns is early onset sepsis and easily combined with multi-organ dysfunction, PLT reduction, and D-dimer elevation.Pathogenic microorganism metagenomic sequencing technology is conductive to the diagnosis of the disease, and Azithromycin is effective.

Objective:To summarize the clinical manifestations and diagnosis, treatment experience of vertically transmitted eschar-free scrub typhus in newborns.Methods:A case summary was made.The clinical data of 3 newborns clinically diagnosed as vertically transmitted eschar-free scrub typhus and treated at the Department of Neonatology, the Sixth Affiliated Hospital, Sun Yat-sen University Yuexi Hospital/Xinyi People′s Hospital from August 2022 to July 2024 were retrospectively analyzed.Results:The age of onset of scrub typhus in the 3 newborns was within 24 h after birth.The children presented a fever, the clinical manifestations of early onset sepsis, and also multiple organ damage.Laboratory examination showed that all the 3 children have an abnormal elevation in C-reactive protein, a decrease of blood platelet (PLT) and an increase in D-dimer within 24 h after birth.The diagnosis was confirmed in all the patients via the metagenomic sequencing technology of pathogenic microorganism of blood samples.Two of the 3 children presented hepatomegaly and were treated with Azithromycin.All the children were clinically cured finally.Conclusions:The early clinical manifestation of vertically transmitted eschar-free scrub typhus in newborns is early onset sepsis and easily combined with multi-organ dysfunction, PLT reduction, and D-dimer elevation.Pathogenic microorganism metagenomic sequencing technology is conductive to the diagnosis of the disease, and Azithromycin is effective.

Objective To explore the association of-11377 site single nucleotide polymorphism in promoter region of adiponectin gene and carotid intima-media thickness(CIMT)in patients with type 2 diabetes mellitus.Methods The adiponectin gene-11377C→G polymorphism was identified by PCR-restriction fragment length polymorphism(RFLP)in 504 patients with type 2 diabetes mellitus(250 patients with increased CIMT and254 Datients with normal CIMT). Serum lipid and fasting plasma glucose were detected by full automatic biochemical analysor.fasting serum insulin(FINS) was measured by radioimmunoassay,and serum adiponectin level was assessed by ELISA.Results The frequencies of adiponectin gene-11377C→G genotype and allele were different between type 2 diabetic patients with normal and increased CIMT(P